Patents Examined by Christina Bradley
-
Patent number: 10925923Abstract: The present invention provides a peptide having anti-inflammatory activity, composed of an amino acid sequence of a sequence listing of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. The peptide inhibits the expression of inflammatory cytokines and inhibits the proliferation of inflammatory cells, so as to resultantly exhibit anti-inflammatory activity, thereby being useful in the prevention or treatment of inflammatory diseases.Type: GrantFiled: March 29, 2017Date of Patent: February 23, 2021Assignee: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim
-
Patent number: 10913769Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.Type: GrantFiled: July 9, 2018Date of Patent: February 9, 2021Assignee: Cara Therapeutics, Inc.Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
-
Patent number: 10905770Abstract: The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin).Type: GrantFiled: July 17, 2018Date of Patent: February 2, 2021Assignee: MacRegen, Inc.Inventors: Keith Roizman, John Jacob Requard, III, Felicity Jane De Cogan
-
Patent number: 10898550Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.Type: GrantFiled: April 11, 2019Date of Patent: January 26, 2021Assignees: CASE WESTERN RESERVE UNIVERSITY, VERSITECH LIMITEDInventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
-
Patent number: 10898583Abstract: Provided are compositions and methods for promoting tolerance to auto-immune antigens. In general the compositions include quantum dots (QDs) that are in association with auto-immune peptide antigens. It is shown that QDs can be used to generate immunological tolerance by controlling the density of self-antigen on QDs. Peptide-QDs rapidly concentrate in draining lymph nodes, and co-localize with macrophages expressing scavenger receptors involved intolerance. Treatment with peptide-QDs reduces disease incidence 10-fold. The degree of tolerance and the underlying expansion of regulatory T cells correlates with the density of myelin molecules presented on QDs such that higher numbers of tolerogenic particles displaying lower levels of self-peptide are more effective for inducing tolerance than fewer particles each displaying higher densities of peptide. The disclosure is therefore relevant to promoting tolerance to antigens that are involved in a variety of autoimmune disorders.Type: GrantFiled: April 18, 2017Date of Patent: January 26, 2021Assignees: University of Maryland, College Park, The Government of the United States of America, as represented by the Secretary of the NavyInventors: Christopher M. Jewell, Krystina Hess, Igor Medintz, Kimihiro Susumu, Eunkeu Oh
-
Patent number: 10898542Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.Type: GrantFiled: December 24, 2019Date of Patent: January 26, 2021Assignee: AFFILOGICInventor: Olivier Kitten
-
Patent number: 10889620Abstract: Solid state forms of Linaclotide, processes for their preparation, compositions comprising them and medical uses thereof are provided. The solid state forms of Linaclotide are useful in the preparation of other solid state forms of Linaclotide, particularly the amorphous form.Type: GrantFiled: July 1, 2016Date of Patent: January 12, 2021Assignee: NOVETIDE LTD.Inventors: Chaim Eidelman, Hagi Alon, Dov Vayer, Sharon Penias-Navon, Jonathan Enav
-
Patent number: 10882885Abstract: Described herein are novel synthetic molecules, polymers, and compositions comprising silica-binding peptides, and their methods of production. Also described herein are methods of synthesizing structurally and chemically complex silica-based materials using the synthetic molecules, polymers, and compositions.Type: GrantFiled: February 15, 2018Date of Patent: January 5, 2021Assignee: Massachusetts Institute of TechnologyInventors: Andrea Kimi Wallace, Maiko Furubayashi, Christopher A. Voigt
-
Patent number: 10870678Abstract: The present disclosure provides certain chiral peptide agents, and uses relating thereto.Type: GrantFiled: April 10, 2017Date of Patent: December 22, 2020Assignee: Arcuate Therapeutics, Inc.Inventor: Andrew D. Levin
-
Patent number: 10858393Abstract: According to the present invention, a crystal of reduced glutathione having a reduced content of impurities, particularly L-cysteinyl-L-glycine and a method for producing the same are provided. The present invention relates to a crystal of reduced glutathione, wherein, in a high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to the peak area of reduced glutathione which is taken as 100.Type: GrantFiled: March 10, 2017Date of Patent: December 8, 2020Assignee: KYOWA HAKKO BIO CO., LTD.Inventors: Kazunari Fukumoto, Maya Iguchi, Hiroshi Nagano
-
Patent number: 10858655Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: GrantFiled: October 29, 2018Date of Patent: December 8, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jeffrey H. Rothman, Gary K. Schwartz
-
Patent number: 10844105Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.Type: GrantFiled: June 23, 2020Date of Patent: November 24, 2020Assignees: University of Washington, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
-
Patent number: 10828296Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: October 2, 2019Date of Patent: November 10, 2020Assignee: Ampio Pharmaceuticals, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Patent number: 10821065Abstract: The present invention relates to: a composition for inhibiting biofilms, containing, as an active ingredient, a peptide derived from human ?-defensin-3; and a method for inhibiting biofilms by using the composition. The peptide according to the present invention inhibits bacterial biofilms even when used alone and exhibits a remarkably increased biofilm inhibitory effect when used in combination with a conventional dental therapeutic agent, and has an effect of preventing a tooth discoloration side effect caused by a conventional dental therapeutic agent.Type: GrantFiled: March 19, 2018Date of Patent: November 3, 2020Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NIBEC CO., LTD.Inventors: Seung Hyun Han, Kee-Yeon Kum, Ki Bum Ahn, Ok-Jin Park, Chong-Pyoung Chung, Yoon Jeong Park, Jue-Yeon Lee
-
Patent number: 10813976Abstract: The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.Type: GrantFiled: September 22, 2017Date of Patent: October 27, 2020Assignee: NOVALIQ GMBHInventors: Frank Löscher, Ralf Grillenberger, Johan Engblom
-
Patent number: 10815283Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.Type: GrantFiled: October 29, 2019Date of Patent: October 27, 2020Assignee: Follicum ABInventors: Jan Alenfall, Pontus Dunér, Anna Hultgårdh Nilsson, Björn Walse
-
Patent number: 10808039Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: July 10, 2019Date of Patent: October 20, 2020Assignee: Seattle Genetics Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
-
Patent number: 10808017Abstract: 53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.Type: GrantFiled: January 31, 2017Date of Patent: October 20, 2020Assignees: The Governing Council of the University of Toronto, Sinai Health SystemInventors: Daniel Durocher, Sachdev Sidhu, Wei Zhang, Frank Sicheri, Marella Canny
-
Patent number: 10800822Abstract: Synthetic histatins composed of combinations of functional domains of natural histatins separated by exogenous linkers are described as are methods of using endogenous and synthetic histatins for the treatment of ocular diseases or conditions.Type: GrantFiled: November 29, 2016Date of Patent: October 13, 2020Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Vinay Aakalu
-
Patent number: 10793596Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.Type: GrantFiled: November 26, 2018Date of Patent: October 6, 2020Assignee: Cara Therapeutics, Inc.Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo